Purple Biotech (PPBT) has released an update.
Purple Biotech, a NASDAQ/TASE-listed company, is poised to deliver multiple clinical data readouts in 2024 for its first-in-class oncology drugs, with a strong cash position ensuring operations into the third quarter of 2025. The company is advancing a robust pipeline, including a promising CEACAM1 inhibitor for pancreatic cancer, and has identified potential biomarkers for its therapies. With a focus on treating cancers with high unmet medical needs, Purple Biotech is strategically positioned in the market with a lean global operation.
For further insights into PPBT stock, check out TipRanks’ Stock Analysis page.
